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Brainstem tumors represent 10–15% of pediatric central nervous system tumors and 
diffuse intrinsic pontine glioma (DIPG) is the most common brainstem tumor of child-
hood. DIPG is almost uniformly fatal and is the leading cause of brain tumor-related 
death in children. To date, radiation therapy (RT) is the only form of treatment that offers 
a transient benefit in DIPG. Chemotherapeutic strategies including multi-agent neoad-
juvant chemotherapy, concurrent chemotherapy with RT, and adjuvant chemotherapy 
have not provided any survival advantage. To overcome the restrictive ability of the intact 
blood–brain barrier (BBB) in DIPG, several alternative drug delivery strategies have been 
proposed but have met with minimal success. Targeted therapies either alone or in com-
bination with RT have also not improved survival. Five decades of unsuccessful therapies 
coupled with recent advances in the genetics and biology of DIPG have taught us several 
important lessons (1). DIPG is a heterogeneous group of tumors that are biologically dis-
tinct from other pediatric and adult high grade gliomas (HGG). Adapting chemotherapy 
and targeted therapies that are used in pediatric or adult HGG for the treatment of DIPG 
should be abandoned (2). Biopsy of DIPG is relatively safe and informative and should 
be considered in the context of multicenter clinical trials (3). DIPG probably represents 
a whole brain disease so regular neuraxis imaging is important at diagnosis and during 
therapy (4). BBB permeability is of major concern in DIPG and overcoming this barrier 
may ensure that drugs reach the tumor (5). Recent development of DIPG tumor models 
should help us accurately identify and validate therapeutic targets and small molecule 
inhibitors in the treatment of this deadly tumor.
Keywords: diffuse intrinsic pontine glioma, blood–brain barrier, pediatric neuro-oncology, brain tumor, re-
irradiation
iNTRODUCTiON
The anatomic brainstem includes three distinct regions: the midbrain, pons, and medulla oblongata. 
Tumors of the brainstem constitute approximately 10–15% of all central nervous system (CNS) 
tumors in children ages 0–14  years in the USA; the majority of these tumors are of glial origin 
(gliomas) (1). Prior to modern imaging techniques, all brainstem gliomas were regarded as a single 
pathological entity, and the prognosis was considered uniformly poor. Computerized tomography 
(CT) and Magnetic Resonance Imaging (MRI) have been used to classify brainstem tumors based on 
their growth pattern and amenability to surgical resection. Diffuse intrinsic pontine gliomas (DIPG) 
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are the most common brainstem tumors in children and account 
for greater than 80% of brainstem gliomas in this age group. The 
widespread infiltrative nature of this tumor, predominantly high-
grade features, coupled with its critical anatomic location and 
inoperability, has led to a uniformly poor outcome in children 
with DIPG.
Clinical Features/Diagnosis
DIPG occurs in all age groups but is most commonly diagnosed 
in children between the ages of 5 and 10  years. There is equal 
predilection for both sexes (M:F =  1:1), and the prognosis is 
significantly worse than that of other brainstem tumors. Due 
to local infiltration and brainstem localization, DIPGs are not 
amenable to surgical resection. The clinical features of patients 
with brainstem tumors vary with respect to tumor location and 
the nature/pattern of growth of these tumors. Patients with DIPG 
have a short latency (usually <2–3 months) between the onset of 
clinical symptoms and diagnosis. The classic triad of symptoms 
includes cerebellar signs (e.g., ataxia, dysmetria, dysarthria), long-
tract signs (e.g., increased tone, hyperreflexia, clonus, Babinski 
sign, motor deficit, etc.), and isolated or multiple cranial nerve 
palsies (unilateral or bilateral), more commonly sixth and seventh 
cranial nerve palsies. Patients with diffuse brainstem tumors 
associated with neurofibromatosis type 1 (NF1) may mimic 
DIPG on imaging. However, in the context of NF1, these are 
usually low-grade gliomas (LGG, WHO grades I–II) that can be 
asymptomatic or diagnosed in the context of an insidious history 
of isolated cranial nerve palsy or motor deficit. Careful clinical 
examination for the stigmata of NF-1 and family history should 
help in the identification of these lesions that usually do not 
require any active treatment. In DIPG, signs and symptoms of 
increased intracranial pressure (due to obstructive hydrocepha-
lus from expansion of the pons) are seen in <10% of children. 
Various other non-specific symptoms present either at the time 
of diagnosis or at the time of progression include sensory abnor-
malities, behavioral changes, urinary problems, declining school 
performance, and respiratory symptoms including sleep apneas.
Over the years, many classification schemes have been pro-
posed for brainstem tumors, and most have utilized the best 
neuroimaging modalities available at the time of classification (2). 
The earliest classifications relied on CT and surgical observations; 
however, the more recent schemes include MRI. In the broadest 
sense, these tumors are divided into two groups, either focal or 
diffuse. The more complex schemes subdivide these tumors by 
location within the brainstem (midbrain, pons, or medulla), 
growth pattern (intrinsic or exophytic), direction and extent of 
tumor growth, the presence or absence of contrast enhancement, 
and the presence of hemorrhage or hydrocephalus (3). In one of 
the most recent classifications proposed by Choux et al. based on 
both CT and MRI characteristics, brainstem tumors are divided 
into four types (4). DIPGs are classified as type I tumors (not to be 
confused with WHO grade I). These lesions appear hypointense 
on CT with non-delineated borders and do not significantly 
enhance on T1-weighted MRI sequences with gadolinium as the 
contrast reagent. DIPGs are characterized by diffuse infiltration 
and swelling of the brainstem.
why will Biopsy of DiPG Become 
important?
Historically, in the pre-CT and MRI eras, stereotactic brainstem 
biopsies were performed on a routine basis for histological 
diagnosis of DIPG. Due to the heterogeneity of these tumors, 
the significant morbidity potentially associated with the biopsies, 
the limited therapeutic options available based on biopsy results, 
the prevalence of poor candidates for biopsy at the time of pres-
entation (i.e., those with focal neurological deficits, increased 
ICP), and the widespread availability of MRI with characteristic 
imaging findings, routine biopsy as the standard of care was 
discontinued in the early 1990s (5).
Safety and Feasibility of the Procedure
Many centers in Europe have been performing routine diagnostic 
biopsies of children with suspected DIPG. In two of the largest 
series of brainstem tumor biopsies in children (6, 7), there were 
only transient reversible morbidities (in <10% of patients) and no 
mortality reported. In a retrospective analysis, Cartmill et al. (6) 
reviewed 18 brainstem glioma patients who underwent CT-guided 
stereotactic biopsy. All 18 patients had a histological diagnosis of 
glioma [HGG, n = 13 (glioblastoma multiforme, GBM = 8; ana-
plastic astrocytoma (AA), n = 5) and low grade gliomas, n = 5]. 
Besides the five patients who developed a transient increase in their 
neurological deficits post-operatively (hemiparesis, increased eye 
movements, and VII nerve palsy), there was no mortality reported. 
Roujeau et  al. (7) reported a prospective series of 24 patients 
with DIPG who underwent stereotactic biopsy. In two patients, 
a diagnosis of low-grade gliomas was made (LGG and pilocytic 
astrocytoma) and each was followed with an initial period of 
observation before initiating radiotherapy. Only two patients had 
transient post-operative neurological deficits (cranial nerve palsy 
and exacerbation of pre-operative hemiparesis) and no deaths were 
reported. A historical cohort study by Cage et al. (8) of nine patients 
with DIPG who underwent stereotactic biopsy revealed no intra-
operative complications and only one patient with post-operative 
neurological deficit (seizures with hydrocephalus), not directly 
related to the procedure. In their review of literature, Cage et al. 
(8) report >300 pediatric cases of DIPG who underwent biopsy 
with mortality attributable to the procedure in only two cases. In a 
recent retrospective series from Wang et al., only 3 of the 15 cases 
of DIPG who underwent biopsy had transient new or worsening 
neurological deficits and there was no biopsy related mortality 
(9). Careful pre-operative planning using functional imaging like 
Diffusion Tensor Imaging tractography to delineate the white mat-
ter (especially corticospinal tracts) and PET imaging to identify 
regions of interest will further decrease the morbidity and increase 
the diagnostic yield of the biopsy (10, 11). The post-operative 
morbidity of image guided stereotactic biopsy of intrinsic pontine 
lesions is comparable to biopsy procedures in other brain locations.
Sampling Bias, Diagnostic Yield and 
Differential Diagnosis
In all of the biopsy series of DIPG cases (6–9), the pathologic 
diagnosis revealed low grade as well as HGG. Initial concerns 
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regarding the heterogeneity of the tumor leading to sampling bias 
and downgrading of the tumor (from WHO grade IV to grade 
II) resulting in less intense therapy, may no longer be considered 
valid. Recent data from a large series of patients suggests that 
there are distinct histologic subgroups of DIPG with varying 
clinical and molecular features (12). Although the patients may 
present with typical clinical features of DIPG, the histopathology 
is diverse (spectrum from grade II to IV) and low grade tumors 
can behave clinically as aggressively as HGGs (8, 12). There is 
potential intra-tumor histologic heterogeneity seen in DIPG as 
demonstrated in the series by Buczkowicz et  al. (12). Tumors 
with classic GBM histology show grade II or grade III histology 
in some areas, which may be selected by biopsy. Furthermore, 
these heterogeneous tumors had classic GBM histologic features 
in the pons but demonstrated low grade astrocytoma (II) or AA 
(III) features in the thalamus or brainstem. These observations 
suggest that histologic grading using current WHO criteria may 
not be appropriate for diagnostic purposes in DIPG. The diag-
nostic yield of biopsy specimens in DIPG is very high (90–100%) 
(13). Although the amount of tumor tissue obtained is limited 
by the needle size, it is usually sufficient to make a histopatho-
logic diagnosis. Moreover, recently described biopsy techniques 
permit multiple biopsies under one anesthetic, thereby providing 
sufficient tissue not only for diagnosis but also for molecular 
studies and primary cell culture (8, 13). Apart from gliomas 
(grade II–IV), Primitive Neuro-ectodermal Tumors (PNET) (9, 
10, 12) and rarely germ cell tumors (including germinomas and 
teratomas) can present as diffuse infiltrative brainstem tumors; 
the management of these tumor entities is different than for glio-
mas. Non-malignant conditions presenting as brainstem lesions 
include neurodegenerative conditions (Alexander disease, acute 
demyelinating encephalomyelitis, central pontine myelinolysis) 
and infections (such as paracoccidioidomycosis) (14).
Areas of Controversy
Some neurosurgeons and other clinicians have introduced the 
terms typical and atypical DIPG and advocate for biopsy for 
atypical disease presentations. Literature review on pediatric 
brainstem gliomas suggests the following criteria for a typical 
DIPG: a combination of clinical symptoms and signs with short 
latency <3–6 months – triad of: (1) cerebellar signs, e.g., ataxia, 
dysmetria and dysarthria; (2) long tract signs: hypertonia, hyper-
reflexia, motor deficits; and (3) cranial nerve palsies-isolated or 
multiple sixth, seventh) and radiological findings on MRI: (1) an 
intrinsic, centrally located tumor involving greater than 50–66% 
of the axial diameter of the pons with (2) hypointensity on T1 
images, (3) hyperintensity on T2 images with (4) indistinct tumor 
margins with engulfment of basilar artery and (5) no cystic or 
exophytic components (15–17). However, a survey conducted 
among neurosurgeons revealed that there was no consensus 
regarding what constitutes a typical DIPG on MRI (18). The dif-
ferential diagnosis for a brain stem tumor in a child with unusual 
presentation and atypical findings on neuroimaging include 
embryonal tumors like ATRT, PNET, and non-malignant lesions 
like infections, neurodegenerative conditions and hemangio-
blastomas (9, 10, 12, 14); the management of these conditions 
is entirely different than for gliomas. Focal brainstem tumors 
usually have insidious onset, prolonged latency and atypical 
clinical features like failure to thrive, emesis etc. Hence, it may 
be reasonable for biopsy to be considered in those patients with 
atypical features for whom clinical management decisions would 
change when provided with a diagnosis other than DIPG.
In a child with typical imaging appearance of DIPG, the 
current recommendations are to offer upfront biopsy only in a 
clinical trial setting (19).
The ability to identify the whole mutational landscape of DIPG 
using tissue obtained by small-needle pretreatment biopsies (20) 
coupled with availability of antibodies to detect (a) K27M muta-
tions in both Histone 3 (H3) variants (H3.3 and H3.1) (21, 22) 
and (b) loss of tri-methylation (anti-HEK27me3) due to these 
mutations provides opportunities to improve diagnosis, assign-
ment of prognosis, and identification of potentially druggable 
targets (PDGFRA, ACVR1, and FGFR1) (12). There is sufficient 
evidence in the literature to suggest that as the field moves forward, 
testing for H3K27M mutations will help in diagnosis (12, 23), 
stratification into subgroups (12, 24) and prognosis (12, 23) and 
will be included in the design of prospective clinical trials testing 
new agents and treatment approaches. In the future, clinical and 
molecular subgroup-based patient stratification in multi-center 
clinical trials of DIPG will include stereotactic biopsy when it is 
considered safe to proceed in individual patients.
iS DiPG A wHOLe BRAiN DiSeASe?
The concept of focal radiotherapy of DIPG is based in part by 
reports suggesting that the tumor mostly spreads by contigu-
ity and the recurrence is mostly local, within the radiotherapy 
fields (25–27). Since distant failure is not considered a common 
phenomenon in the natural history of DIPG, patients do not 
routinely undergo neuraxis imaging either at diagnosis or follow 
up after initial therapy. Leptomeningeal dissemination/disease 
(LMD) was reported in 4–33% of patients in the pre-MRI era 
(25–27). In contrast, several studies have identified widespread 
CNS disease by autopsy and/or neuroimaging (12, 28–35). In fact, 
disseminated disease may be seen (1) at the time of diagnosis; 
(2) during follow-up while on treatment; or (3) at the time of 
autopsy. Benesch et  al. (30) in their retrospective data analysis 
of HGGs report an incidence of 3.1% (N = 10/546, HGG = 348, 
DIPG = 198) of patients with primary dissemination at diagnosis. 
However, there was only one case of DIPG (n =  1/198, 0.5%) 
with distant spread (lateral ventricle). Sethi et al. (33) reported 
3/9 patients (33%) who had LMD detected at diagnosis. In the 
same series, prospective neuraxis surveillance (MRI of brain and 
spine) at 4-month intervals after completion of therapy revealed 
local failure in 75% of patients (12/15) and LMD in six patients 
(6/9, 66%). Moreover, patients with LMD had shorter overall 
survival (OS) when compared to patients with localized disease: 
12.0 ± 3.3 months without LMD and 8.0 ± 2.1 months with LMD 
(P = 0.059). Donahue et al. (28) reported 15/18 (83%) children 
with DIPG with progression of disease of which 14 had local fail-
ures. The protocol on which these children were treated mandated 
monitoring with neuraxis surveillance MRIs every 4 months after 
completion of treatment. Interestingly, none of these patients 
had clinical evidence of LMD. The authors concluded that LMD 
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occurs primarily in the setting of local progression and therapy 
should be directed primarily toward improving local control.
Wagner et al. (31) reported secondary disseminating disease 
(SDD) in DIPG in 13% of their patients (14/110). The median 
time between diagnosis and SDD was 7.2  months (range, 
4.6 months to 2.2 years) and there was parenchymal metastasis 
involving the supratentorial, infratentorial, and spinal regions 
along with LMD. DIPG patients who had LMD and ventricular 
tumor spread had decreased OS when compared to patients who 
had parenchymal metastasis. However, SDD did not reduce OS in 
DIPG tumors, suggesting that rapid local progression of disease 
is probably the main cause of shortened survival. Gururangan 
et al. (32) in a retrospective review of neuraxis dissemination in 
DIPG found metastatic disease in 17.3% (18/96) patients. All the 
patients died of disease at a median of 5 months (range, 0.5–20) 
from the diagnosis of neuraxis spread. The pattern of spread 
showed both LMD and parenchymal involvement. Yoshimura 
et  al. (29) in their autopsy series of DIPG reported more than 
50% of patients had disseminated disease with supratentorial 
spread in 45% (18/40) and LMD in 32.5% (13/40). Almost all 
the cases except one were HGGs (GBM = 34, AA = 5). Caretti 
et  al. (35) in their autopsy series of 16 DIPG patients found 
widespread extension involving the midbrain/medulla (63%), 
cerebellum (56%), thalamus (56%), frontal cortex (25%), and 
supratentorial leptomeninges (25%). There was disease spread 
into the spinal cord in two out of the three patients examined. 
A unique form of sub-ventricular spread resulting in tumor 
nodules seen in the frontal horns of the lateral ventricles was 
observed in 10 of 16 cases (62.5%). In one of the largest series of 
DIPG (12), 38% of patients exhibited LMD of their tumor. There 
was parenchymal spread in the form of diffuse involvement of 
brainstem, spinal cord and supratentorial (thalamus and frontal 
lobe) regions. There was no association between histology and 
LMD. However, there were TP53 mutations in 6 of the 11 patients 
tested and none of the patients with LMD were found to have the 
ALT (alternate lengthening of telomeres) phenotype. Histone H3 
K27M mutations in H3.3 were seen in 67% (35/52) and in H3.1 
were seen in 15% (8/52). Histone H3 mutations were observed in 
all histology grades of DIPG (II–IV): 88% in GBM, 60% of AA, 
and 71% of low grade astrocytomas. K27M-H3.3 mutations were 
higher in GBM patients (78%) when compared to AA histology 
(33%) (P = 0.0016). Importantly, low grade tumors carrying H3.3 
mutations had OS similar to that of GBM tumors and patients 
with high grade tumors with wild-type H3.3 had OS comparable 
to wild-type low grade astrocytomas (12).
Diagnostic and Therapeutic implications
At the time of diagnosis, whenever available, biopsy specimens 
of DIPG are suggested to be tested for Histone K27M mutations 
(H3.3 and 3.1) along with routine WHO histological grading and 
other markers (TP53, PDGFRA, ACVR1, and FGFR1). This will 
help in obtaining the correct diagnosis, proper patient selection 
for clinical trials (for risk stratification and targeted therapies) 
and prognosis (12, 36). Neuroimaging at the time of diagnosis 
should include MRI of the brain; the spine may be included at 
the discretion of the attending physician. Thereafter, regular 
interval neuraxis imaging during follow-up could be included in 
prospective clinical trials to better understand the natural history 
of DIPG progression, including disease dissemination. This data 
may help guide therapy decisions and prognosis.
The majority of DIPG patients treated with focal brainstem 
radiotherapy (RT) relapse locally. There are several reports, which 
suggest that sub-lethal irradiation (IR) promotes migration of 
glioma cells (37–40). Wild-Bode et al. (37) proposed that tumor 
cells stimulated to invade by sub-lethal doses of irradiation may 
escape the target volume of post-operative RT, thereby evading 
delivery of a cumulative lethal dose and forming the basis for 
loco-regional relapse a few months after RT. These infiltrative 
tumors are less proliferative as shown by few mitoses and scarce 
MIB1 immunopositivity (12). Therefore, concurrent anti-
invasive/anti-migratory therapies (cell cycle/check point inhibi-
tors, glycogen synthase kinase-3 inhibitors: lithium chloride and 
6-bromoindirubin-oxime) along with RT have been suggested to 
be beneficial in these patients potentially improving the efficacy 
of RT (40, 41).
The question of whether to offer focal vs. cranio-spinal RT 
in DIPG cannot be currently answered due to the paucity of 
data. Benesch et al. (30) in their series of HGG (including one 
patient with DIPG) did not observe a statistically significant dif-
ference in the progression free survival (PFS) and OS between 
patients with and without tumor dissemination at diagnosis. 
Hence, their recommendation was to treat both the groups in 
the same manner (focal IMRT). Similarly, data from the German 
registry (42) comparing six HGG patients who had metastasis at 
diagnosis (two patients with DIPG) and underwent intensified 
chemo-radiotherapy (CSI ±  local boost to tumor deposits with 
concurrent metronomic temozolomide) demonstrated inferior 
results when compared to the Benesch series (30). In the future, 
a multi-centered randomized clinical trial to address the issue 
of appropriate clinical target volume (CSI vs. focal RT) in DIPG 
may be considered. Although recurrence of tumor (either locally 
or at distant sites) has shorter OS, CNS prophylaxis in the form of 
regular intra-thecal chemotherapy (43) similar to acute lympho-
blastic leukemia (ALL) therapy is not recommended.
TReATMeNT
Diffuse intrinsic pontine glioma is almost invariably fatal with a 
mean OS of 8–14 months from the time of diagnosis. Radiation 
therapy (RT) prolongs survival by a mean of 3–6  months, but 
is still considered aggressive palliative therapy. A number of 
adjuvant therapies such as chemotherapy, targeted therapies, dif-
ferentiation agents and radiation sensitizers have been studied, 
but none of them have had any significant impact on patient 
outcomes. There is no role for surgery in a typical case of DIPG. 
However, recent advances in understanding the biology of these 
tumors and availability of targeted therapies may warrant biopsy 
at diagnosis in some patients in order to personalize therapy and/
or enroll the child in a clinical trial.
Radiation Therapy
The current standard of care for newly diagnosed DIPG patients is 
fractionated focal intensity modulated radiation therapy (IMRT) 
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to the tumor along with 1–2 cm margins (54–60 Gy, 1.8–2 Gy 
fractions, given once daily for 5 days per week over a period of 
6 weeks). Supportive care in the form of corticosteroids is used to 
treat the peri-tumoral edema and is usually weaned after comple-
tion of RT. About 70–80% of patients respond to RT with some 
transient improvement in their neurological symptoms but more 
than half of the patients incur steroid induced side effects. Lower 
doses of RT (<50Gy) have worse outcomes, and higher doses 
using hyper-fractionated RT (66–78 Gy) do not appear to pro-
vide a survival advantage when compared to standard dose and 
fractionation protocols (44–54) (Table 1). It was postulated that 
re-population by rapidly proliferating tumor cells may be a reason 
for local treatment failure and accelerated fractionation (con-
ventional fraction sizes twice daily) was expected to reduce the 
potential for re-population and improve outcomes. Conversely, 
several studies using hypo-fractionation have reported results that 
are similar to those observed with normal fractionation but offer 
no distinct survival benefits (52–54). Although the advantage of 
the hypofractionation technique is reduction in the total dura-
tion of treatment (13–18 fractions instead of 30–33), the major 
disadvantages are the adverse effects of RT on adjacent normal 
tissue. Hyperfractionation usually requires twice daily anesthet-
ics in young children. Following completion of radiation, there is 
clinical progression of disease in almost all cases with radiologic 
evidence of local recurrence within 3–6  months. As discussed 
above, there could be LMD as well as distant parenchymal recur-
rence. Although RT appears beneficial, radiation sensitizers have 
not shown any improvement in outcomes to date. The use of RT 
concurrently with radio-sensitizers such as platinum compounds 
(carboplatin), topoisomerase inhibitors (etoposide, trofosfamide, 
topotecan), and other agents (metronomic temozolomide, etani-
dazole) has not been successful (Tables 1 and 3A,B).
Feasibility of Palliative Re-Irradiation in DIPG
There is evidence suggesting that re-irradiation in pediatric 
brain tumors (posterior fossa ependymoma, EP) is well toler-
ated and provides durable local tumor control (55, 56). Median 
time from first to second irradiation was 21.9  months (range, 
7.5–67.7  months) (55) in one series and 26  months (range, 
13–88  months) in another series (56). The median re-RT dose 
for focal fractionated re-irradiation (FFRT) was 55.2 Gy (range, 
50.4–54 Gy) with a cumulative dose of 87–113 Gy to the brain 
stem and none of the patients had radiation necrosis (55).
Based on these studies in ependymoma and in the absence of 
effective treatment options for recurrent DIPG, some institutions 
are providing palliative re-irradiation with/without concurrent 
chemotherapy for DIPG (57, 58). Fontanilla et al. (57) treated six 
recurrent DIPG patients (clinical and MRI confirmation) with 
chemo-radiotherapy followed by post RT chemotherapy. The 
time to initial progression from the completion of first RT was 4 
to 18 months and the time interval between initial RT and re-RT 
was 8–28 months. The re-RT dose was between 18 Gy (n = 1) 
to 20 Gy (n = 4). There was good symptomatic response in four 
of the six patients with improvement in speech, swallowing and 
ambulation. The median clinical progression-free survival (PFS) 
time was 5  months and there were minimal RT related side 
effects with no Grade 3–4 toxicities reported. Massimino et al. 
(58) re-irradiated 11 of their 16 locally relapsed DIPG patients. 
There was tumor volume shrinkage in 7 cases and steroids were 
weaned completely in 10 cases. The median survival after re-RT 
was 6 months (range, 6 weeks to 14 months) and none of the re-
irradiated patients showed any evidence of worsening symptoms 
or unexpected side effects. Preferred candidates for re-irradiation 
in DIPG may include those children who have experienced 
durable responses to prior radiation without evidence of clinical/
radiological progression off therapy (57, 59).
We analyzed data on 10 patients of recurrent DIPG treated 
with re-RT across different centers in Canada (Table  2; 60). 
Median time from diagnosis to progression was 12  months 
(range, 4–37  months) in this cohort, exceeding median time 
to progression in historical controls. Re-irradiation total dose 
varied between institutions from 21.6  Gy (n  =  2), 30.6  Gy 
(n = 6), and 36 Gy (n = 2), administered in 1.8 Gy daily fractions. 
Re-radiation was to the involved field except in two patients who 
received whole brain irradiation due to distant/disseminated 
relapse. One patient received a third course of focal radiation 
(21.6 Gy) 6 months after re-radiation. Re-irradiation was toler-
ated very well by all patients. Four patients had transient fatigue 
and decreased appetite during treatment. All but one showed 
neurological improvement, with four patients showing full 
recovery. With a median follow-up from diagnosis of 19.5 months 
(range, 9–45 months), seven patients died, with a median time 
from re-irradiation to death of 9 months (range, 5–13 months). 
When compared to an historic cohort of 46 patients, median 
time from progression to death was 91.5 days in the non re-irra-
diated patients, vs. 171 days in the re-irradiated ones (P < 0.05). 
Although these preliminary results are encouraging, they are 
from small pilot studies and remain to be confirmed in a clini-
cal trial setting. Although we do not suggest that re-irradiation 
should become the standard of care, based upon published and 
unpublished results, we encourage the development of prospec-
tive cooperative group Phase II studies offering re-irradiation so 
that this treatment option can be properly studied from a safety 
and efficacy perspective. Based on the above data, a dose range 
from 30 to 36 Gy in 16 to 20 fractions (1.8 Gy per fraction) at the 
time of recurrence may be a reasonable approach that is feasible 
and well tolerated.
Chemotherapy
Different chemotherapeutic strategies including high-dose 
myeloablative chemotherapy with stem cell rescue, neo-adjuvant 
(pre-RT) multi-agent chemotherapy, concurrent chemotherapy 
with RT (fractionated/hyper-fractionated protocols), and adju-
vant chemotherapy have not demonstrated improved survival 
when compared to RT alone [Tables  3A,B (61–90)]. In par-
ticular, the current standard of care for adult GBM, namely RT 
with concurrent and adjuvant temozolomide, did not improve 
outcomes for DIPG [(91, 92), Table 4]. Various studies utilizing 
both neo-adjuvant and concurrent chemotherapies have shown 
no improvement in the OS of DIPG patients when compared to 
standard RT. Two French studies showed improved results using 
chemotherapy with RT when compared to RT alone. Doz et al. 
(65) used Carboplatin prior to and concurrently with RT in 38 
DIPG patients and reported a median survival of 11  months 
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TABLe 1 | Radiation therapy in DiPG.
Reference Year/phase Number of 
patients (N)
Treatment: total dose (Gy)/total 
fractions/dose per fraction (Gy)
imaging Outcome Comments
Jenkin et al. (44) 1987/RCT 33 50–60/–/0.8–0.9 CT OS: 20% Patients randomized to RT with and without adjuvant 
chemotherapy: CCNU, vincristine and prednisone
Procarbazine was given at relapse in patients who 
received chemotherapy only
Brain stem gliomas (including DIPG) were included in the 
study
Packer et al. (45) 1987/pilot 16 64.8/54/1.2 CT/MRI Median PFS: 7 months
Freeman et al. 
(46)
1988/I–II 34 66/60/1.1 CT MST: 11 months
OS at 1 year: 48%
Brain stem gliomas (including DIPG) were included in the 
study
Edwards et al. 
(47)
1989/I–II 34 72/72/1 CT/MRI MST: 16 months
Median TTP: 11 months
Brain stem gliomas (including DIPG) were included in the 
study
Freeman et al. 
(48)
1991/I–II 57 70.2/60/1.17 CT/MRI Median TTP: 6 months. MST: 10 months
OS at 1 year – 39.6 ± 6.6%, at 
2 years – 23 ± 5.8%
Packer et al. (49) 1993/I–II 53 72/72/1 CT/MRI OS at 1 year – 38 ± 6.5%, at 
2 years – 14 ± 5.4%, at 3 years – 8 ± 6.5
Freeman CR 
et al. (27)
1993/I–II 39 75.6/60/1.26 MRI Median TTP: 7 months. MST: 10 months
OS at 1 year – 39.9 ± 8.3%, at 
2 years – 7 ± 4.8%
Packer et al. (50) 1994/I–II 66 78/78/1 CT/MRI OS at 1 year – 35 ± 6%, at 3 years – 11 ± 6%
Packer et al. (51) 1996/pilot 32 72/72/1 MRI Median TTP: 5 months Recombinant beta-interferon was used prior to and with 
RT
Brain stem gliomas (including DIPG) were included in the 
study
Lewis et al. (52) 1997/pilot 28 48.6/27/1.8
50.4/28/1.8
CT/MRI MST: 8.5 months
OS at 1 year – 32%, at 2 years – 11%
Brain stem gliomas (including DIPG) were included in the 
study
Biopsy was done in 10 cases with Grade I/II (n = 4) and 
Grade-III/IV (n = 6)
Janssens et.
al. (53)
2009/pilot 9 39/9/3 (n = 8)
33/6/5.5 (n = 1)
MRI Median TTP: 4.9 months
OS: 8.6 months
Biopsy proven Grade IV astrocytomas in four patients
Negretti et.al. 
(54)
2011/– 22 49/15/3 MRI Median TTP: 5.7 months
OS: 7.6 months
CT, computerized tomography; MRI, magnetic resonance imaging; OS, overall survival; PFS, progression free survival; MST, median survival time; TTP, time to tumor progression.
TABLe 2 | Re-irradiation for DiPG (60).
Patient/
sex
Age at Dx Time from Dx to 
Relapse (m)
Time from 
Relapse to start 
re-RT (d)
Dose of 
re-RT 
(Gy)
MRi post 
re-RT
DXM Clinical (neurologic 
symptoms)  
improvement after re-RT
Side effects after 
re-RT
Time from  
re-RT to progression 
(m)
Outcome/
follow up (m)
1/F 6 years 5 
monthsa
14 20 30.6/focal Yes Yes/weaned by end 
of RT
Yes/partial recovery Fatigue, insomnia 6 Dead (25)
2/F 10 years 
3 months
4 12 30.6/focal – Yes/weaned at 
progression
No Vomiting, fatigue, 
weakness
5 Dead (9)
3/F 5 years 9 14 30.6/focal Yes Yes/weaned by end 
of RT
Yes/fully recovered None 3 Dead (15)
4/M 13 yearsb 9c 24 30.6/whole 
brain
Yes Nil Yes/fully recovered None 12 Alive (37)
5/F 4 years 
9 monthsd
32c 75 30.6/whole 
brain
Yes Nil Yes/fully recovered Fatigue, 
decreased energy, 
appetite
7 Dead (45)
6/M 2 years 
3 monthse
13 40 30.6/focal – Nil Yes/fully recovered None – Alive (16)
7/F 5 years 10f 60 21.6/focal Yes Nil No None – Dead (7)
8/M 4 years 
6 monthsg
6 15 21.6/focal Yes Nil Yes/fully recovered None – Dead (4)
9/F 5 yearsh 36 30 36/focal Yes Nil Yes/partial recovery None 3 Dead (4)
10/M 9 yearsh 12 30 36/focal Yes Yes Yes/partial recovery Fatigue 9 Dead (9)
D, days; Dx, diagnosis; Gy, Gray.
aThis patient had a second relapse 6 months after re-RT and received a third course of re-RT with 21.6 Gy.
bStarted on Temozolomide 3 months after re-RT and continued until progression 1 year after re-RT.
cLeptomeningeal/parenchymal dissemination at recurrence.
dAtypical presentation at diagnosis: MRI showed expansive brain stem lesion centered in the pons, and a second non-enhancing lesion in the right cerebellar hemisphere. The lesions were biopsied revealing an anaplastic astrocytoma.
eFavorable prognostic factors at diagnosis: age <3 years and prolonged interval between onset of symptoms and diagnosis (10 months). Biopsy at diagnosis revealed glioblastoma multiforme.
fReceived Bevacizumab (Avastin), biweekly, at the time of relapse for a total of eight doses.
gProlonged interval between onset of symptoms and diagnosis (14 months). The child had an alteration of voice with no other clinical symptoms.
hReceived Valproic acid starting 6 weeks after completion of re-RT.
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TABLe 3 | (A) Summary of clinical trials of neo-adjuvant chemotherapy and RT in DiPG; (B) summary of clinical trials of Chemotherapy (pre-/concurrent/adjuvant) and RT in DiPG.
Reference Year/phase Number of 
patients (n)
Treatment Outcome RT and comments
Kretschmar et al. (61) 
POG-8833
1993/II 32 CDDP/CPM – four cycles followed by 
RT
MST: 9 months RT dose: 66/60/1.1 
Dunkel et al. (62) 1998/pilot 6 BCNU/Etop/Te followed by ABMT and 
RT
MST: 11.4 (7.6–17.1) RT dose: 72–78/72–78/1
Jakacki et al. (63) 1999/II 11 CCNU/P/VCR followed by ABMT and 
RT
MST: 13 months RT dose: 50.4–59.4/–/1.8
Jennings et al. (64) 
CCG-9941
2002/II Group A = 32, 
Group B = 31
A = VCR/Car/Etop
B = CDDP/CPM/Etop/VCR followed 
by RT
EFS at 1 year-17 ± 5%, 
2 years – 6 ± 3%
RT dose: 72/72/1
Doz et al. (65) 2002/pilot 38 Car followed by Car + RT MST: 11 months RT dose: 54/30/1.8
Biopsy in 14 patients (HGG-7, LGG-4)
Grundy et al. 
(66) UKCCSG/
SIOP-CNS9204
2010/II 7 Car/CDDP/CPM/HDMTx/VCR followed 
by RT
Median TTP: 0.21 years (0.1–0.53)
Median OS: 0.3 years (0.25–1.43)
Frappaz et.al. (67), 
SFOP-BSG-98
2008/II 23 BCNU/CDDP/Hydroxyurea/HDMTx/
Tamoxifen followed by RT
MST: 17 months (10–23) RT dose: 54/2/2
Prolonged hospitalization in treated patients
Massimino et al. (68) 2008/II, Study-II 10 CDDP/CPM/Etop/HDMTx/VCR 
followed by RT
MST: 13 months
OS 1 year –70 ± 14%, 
2 years – 10 ± 9%
All patients received adjuvant CCNU/VCR chemotherapy post 
RT
Wolff et al. (69) 
(HIT–GBM-D)
2011/II 7 HDMTx (two doses) followed by 
RT + CDDP/Etop/Ifos/VCR
Median EFS: 0.55 All patients received adjuvant CCNU/VCR/Prednisone 
chemotherapy post RT
Levin et al. (70) 1984/II 28 CCNU/5FU followed by RT MST: 11 months RT dose: 55/31/1.8
Patients received adjuvant hydroxyurea/misonidazole post RT
Brain stem gliomas (including DIPG) were included in the study
Wakabayashi et al. (71) 1992/Pilot 16 RT + ACNU/IFN-β MST: 15.7 months RT dose: 40–60/27–30/1.5–2
Brain stem gliomas (including DIPG) were included in the study
Bouffet et al. (72) 1997/II 8 BCNU-ABMT followed by RT MST: 4 months Patients were previously treated with Chemo/RT
Brain stem gliomas (including DIPG) were included in the study
Walter et al. (73) 1998/I–II 9 RT + Car/Etop Median TTP: 8 months
OS: 1 year – 44%, 2 years – 11%
RT dose: 70.2/60/1.7
Allen et al. (74) 1999/I–II 31 RT + Car Median OS: 12 months RT dose: 72/72/1
Three long-term survivors (mean F/U 79 months)
Jakacki et al. (63) 1999/pilot-II 6 CCNU/P/VCR + ABMT (pre-/during/
post) RT
MST: 11 months RT dose: 50.4–59.4/28–33/1.8
Mandell LR et al. (75) 1999/III 
(randomized)
Group-I = 66, 
Group-II = 64
RT + CDDP Median TTP: 6 months (I)/5 months (II)
OS 1 year –30.9(I)/27(II), 2 years – 7.1 
(I)/6.7(II)
RT dose: Group-I: 54/30/1.8. Group-II: 70.2/60/1.17
This study showed that hyperfractionation has no benefit 
compared to routine fractionation
(Continued)
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Reference Year/phase Number of 
patients (n)
Treatment Outcome RT and comments
Freeman et al. (76), 
POG-9239
2000/II 64 RT with and without CDDP 1 year survival lower in CDDP group 
compared to RT alone
RT dose: 70.2/60/1.7
Brain stem gliomas (including DIPG) were included in the study
Bouffet et al. (77) 2000/Pilot 36 RT followed by Bu/Te and ABMT MST: 10 months RT dose: 54/30/1.8
Brain stem gliomas (including DIPG) were included in the study
Broniscer et al. (78) 2000/II 27 RT + tamoxifen followed by Tamoxifen OS 1 year-37 ± 9.5% RT dose: 54–60/34–36/1.5–1.8
Wolff et al. (79), 
HIT–GBM-A
2002/pilot 20 RT + trophosphamide/Etop OS 1 year-0.4, 4 years-0.05 RT dose: 54/30/1.8
Biopsy in 15 patients (Grade II-4, III-3, IV-8)
Marcus et al. (80) 2003/I 18 RT + Etanidazole MST: 8.5 months (3–58) RT dose: 66/44/1.5
Sanghavi et al. (81) 2003/I 16 RT + Topotecan MST: 15 months (9.6–19)
OS 1 year 53%
RT dose: 59.4/33/1.8
Bernier-Chastagnier 
et al. (82)
2005/II 32 RT + Topotecan MST: 8.3 months OS 1 year 25.5 ± 8% RT dose: 54/30/1.8
Packer et al. (83) 2005/I 13 Car + RMP-7 followed by RT MST: 11 months RT dose: 59.4/33/1.8
RMP-7 (cereport) is a synthetic bradykinin analog that increases 
BBB permeability
Greenberg et al. (84) 2005/I 7 RT + Etop/VCR/cyclosporine-A MST: 11 months RT dose: 54/30/1.8
Cyclosporine was used for P-gp inhibition
Wolff et al. (85), 
HIT–GBM-B
2006/I-II 19 RT + CDDP/Etop/Ifos followed by 
CPM/IFN-γ
MST: 9.6 months RT dose: 54/30/1.8
Warren et al. (86) 2006/II 12 RMP-7 + Car No response in any patient Brain stem gliomas (including DIPG) were included in the study
Turner et al. (87) 2007/II 12 RT + Thalidomide followed by 
Thalidomide
Median TTP: 5 months (2–11)
Median TTD: 9 months (5–17)
RT dose: 55.8/31/1.8
Korones et al. (88) 2008/II 30 RT + VCR/Etop (oral) followed by VCR/
Etop (oral) × 10cycles
MST: 9 months (3–36), OS 
1 year – 27 ± 7%, 2 year –3 ± 2%
RT dose: 54/30/1.8
Massimino et al. (68) 2008/II, study-I
Study-III
Study-IV
21
17
14
RT + Ara-C/Act-D/CDDP/Etop/Ifos
RT + CDDP Etop/isotretinoin (prior/
during and after RT)
RT + vinorelbine (prior/during and after 
RT)
MST: 12 months, OS 1 year – 45 ± 6%, 
2 year – 18 ± 5%
MST: 9 months, OS 1 year – 29 ± 11%, 
2 year –12 ± 8%
MST: 9 months, OS 1 year – 43 ± 13%, 
2 year – 21 ± 11%
RT dose: 54/30/1.8 (n = 18), 66/60/1.1 (n = 3)
RT dose: 54–60/27–30/1.8–2
RT dose: 54–60/27–30/2
Michalski et al. (89) 2009/II 31 RT + tamoxifen (oral) MST: 6.32 months, OS 1 year –16.1% RT dose: 54/30/1.8
Wolff et al. (90), 
HIT–GBM-C
2010/II 37 RT + CDDP/Etop/VCR followed by 
CDDP/Etop/Ifos/valproic acid
Median OS: 1.13 (0.87–1.39) RT dose: 54/30/1.8
OS, overall survival; PFS, progression free survival; MST, median survival time; TTP, time to progression; TTD, time to death; EFS, event free survival; RT, radiation therapy; RT dose, cumulative dose (Gy)/number of fractions/
dose per fraction (Gy); Ara-C, cytosine arabinoside; Act-D, actinomycin D; ACNU, Amino-chloroethyl-nitrosourea hydrochloride; BCNU, Carmustine; Bu, Busulphan; Car, Carboplatin; CCNU, lomustine, CDDP, cisplatin, CPM, 
cyclophosphamide, Etop, etoposide, 5FU-5 Flurouracil; HDMTx, high dose Methotrexate, Ifos, ifosfamide, P, procarbizine, IFN-β, interferon beta; IFN-γ, interferon gamma; Te, thiotepa, ABMT, autologous bone marrow transplant.
TABLe 3 | Continued
O
ctober 2015 | Volum
e 5 | A
rticle 237
9
Vanan and E
isenstat
D
IP
G
: learning from
 the past
Frontiers in O
ncology | w
w
w
.frontiersin.org
TABLe 4 | Concomitant and Adjuvant Temozolomide (TMZ) based chemotherapy in DiPG.
Reference Year/phase Number of 
patients (N)
TMZ dose (mg/m2) with RT/
after RT/number of cycles
Outcome Comments
Lashford  
et al. (93)
2002/II 21 –/200/– MST: 6.2 months All patients received RT
TMZ started at relapse
Broniscer et al. 
(94)
2005/II 33 –/200/6 MST: 12 months
OS: 1 year – 48%
All patients received irinotecan and RT
RT dosing: 50.4–70.8/30/1.8
Sirachainan  
et al. (95)
2008/II 12 75/200/– Median TTP: 10.2 ± 3 months
MST: 13.5 ± 3.6 months
OS: 1 year – 58 ± 4.2%
All patients received cis-retinoic acid.
RT dose: 35.8-59.4 Gy
Jalali et al. (96) 2010/II 20 75/200/12 Median OS: 9.15 months
Median PFS: 6.9 months
RT dose: 54/30/1.8
Chiang et al. (97) 2010/II I = 10
II = 8
75/150/– MST: 12.3 months
OS: 1 year – 51%
I = adjuvant TMZ
II = Concurrent TMZ
Kim et al. (98) 2010/I-II 12 75/200/– MST: 12.7 months
OS: 1 year – 58%
All patients received thalidomide with RT
Sharp et al. (99) 2010/II 15 85/85/– MST: 9.8 months
OS: 1 year – 20%
RT dose: 54/30/1.8
Cohen et al. (91) 
ACNS0126
2011/II 63 90/200/10 MST: 9 months
OS: 1 year – 40%, 2 year – 3.6%
RT dose: 59.4/33/1.8
Chassot  
et al. (92)
2012/II 21 75/200/6 MST: 11.7 months
OS: 1 year – 50%
RT dose: 54/30/1.8
All cases were biopsied
Kebudi  
et al. (100)
2012/
retrospective
21 75/200/12 MST: 12 months
OS: 1 year – 55%, 2 year – 37%
Bailey  
et al. (101)
2013/II 43 75/75–100/12 MST: 9.5 months
OS: 1 year – 35%, 2 year – 17%
Zaky et al. (102) 2013/
retrospective
6 75/200/– Median EFS: 6.1 months.
Median OS: 9.6 months
Patients received concurrent chemo 
(carboplatin/etoposide) followed by 
adjuvant chemo (irinotecan/bevacizumab)
Aguilera  
et al. (103)
2013/report 2 –/200/– PFS: 37/47 months RT dose: 54/30/1.8
Both patients received adjuvant 
bevacizumab and were alive at the time of 
reporting
Tumor size decreased by >65%
Muller  
et al. (42)
2014/II 2 75/–/– MST: 11.9/8.1 months Both patients received nimotuzumab and 
cranio-spinal RT
Rizzo  
et al. (104)
2015/II 14 75/200/12 Median TTP: 7.15 months
OS, overall survival; PFS, progression free survival; MST, median survival time; TTP, time to progression; EFS, event free survival; RT, radiation therapy; RT dose, cumulative dose 
(Gy)/number of fractions/dose per fraction (Gy).
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(compared to 9 months with RT alone). Frappaz et al. (67) used 
frontline chemotherapy (Tamoxifen/BCNU/Cisplatin alternating 
with high dose methotrexate/HDMTX) aimed at delaying radia-
tion until time of clinical progression. Median survival increased 
significantly in patients participating in the protocol compared 
to historical controls (17 vs. 9 months, P = 0.022). However there 
was prolonged hospitalization and increased infections in the 
chemotherapy group. The German HIT–GBM protocols assessed 
a variety of chemotherapeutic strategies in the HIT–GBM proto-
cols (A–D) in the treatment of DIPG and could not demonstrate 
any survival benefit when compared to RT alone (69, 79, 85, 90). 
In a single institution study over two decades Massimino et al. 
(68), evaluated four different regimes in the treatment of DIPG: 
(1) intensive high-dose courses of chemotherapy (cisplatin/
etoposide, cyclophosphamide/vincristine/methotrexate) and a 
subsequent course of myeloablative thiotepa followed by RT and 
maintenance chemotherapy; (2) cisplatin/etoposide followed 
by isotretinoin before, during, and after focal RT; (3) concur-
rent chemo-radiotherapy (etoposide, cytarabine, ifosfamide, 
cisplatin, and dactinomycin); and (4) Vinorelbine before, during, 
and after radiotherapy. The median survival time was reported as 
11 months with no survival advantage within protocols compared 
with RT alone (Tables 3A,B).
Various clinical trials using Temozolomide (TMZ) in com-
bination with concurrent RT followed by adjuvant TMZ have 
shown variable results (91–104) (Table  4). Kebudi et  al. (100) 
in their retrospective analysis of 50 DIPG patients treated with 
RT and TMZ with and without other chemotherapy showed 
TABLe 5 | Biological/targeted therapies in DiPG.
Target Agent Newly diagnosed or progressive/relapsed, 
number of patients (n) 
Median PFS 
(months)
PFS at  
6 months (%)
Reference
EGFR Erlotinib Newly diagnosed with RT 8 90 Geoerger et al. (115)
Gefitinib Newly diagnosed with RT (n = 43) 7.4 88 Pollack et al. (116)
Newly diagnosed with RT (n = 20) NR 48 Geyer et al. (117)
Nimotuzumab Newly diagnosed with RT (n = 41) 5.5 NR Massimino et al. (118)
Progressive/relapsed (n = 44) 1.7 NR Bartels et al. (119)
EGFR/VEGFR Vandetanib Newly diagnosed with RT (n = 21) NR 88 Broniscer et al. (120)
PDGFRA Imatinib Newly diagnosed with RT NR 70 Pollack et al. (121)
VEGF Bevacizumab Progressive/relapsed (n = 31)
Progressive/relapsed (n = 2)
Newly diagnosed with RT (n = 14) 
2.3
2.25
8.8
9.7
NR
NR
Gururangan et al. (122)
Narayana et al. (123)
Salloum et al. (124)
mTOR Temsirolimus Progressive/relapsed (n = 5) 2.5 NR Geoerger et al. (125)
Farnesyl transferase Tipifarnib Newly diagnosed with RT (n = 40) NR 44 Haas-Kogan et al. (126)
Integrins (αvβ3 and αvβ5) Cilengitide Progressive/relapsed (n = 31) NR NR MacDonald et al. (127)
Histone de-acetylase 
(HDAC)
Valproic acid
Panabinostat
Newly diagnosed with RT/chemotherapy 
Murine DIPG models
9.5
–
NR
–
Felix et al. (128)
Grasso et al. (129)
PFS, progression free survival; RT, radiation therapy; NR, not recorded.
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significantly higher OS in the TMZ treated group. Patients 
receiving RT + TMZ + chemotherapy (other than TMZ) showed 
prolonged survival when compared to patients receiving only 
RT (P =  0.005). However a number of other studies (Table  4) 
have reported no distinct survival advantage of RT + TMZ when 
compared to RT alone. The HIT-HGG-2007 study is a non-
inferiority clinical trial designed to prove the hypothesis that 
ambulatory TMZ-chemoRT is as effective, but less toxic than 
the previous HIT–GBM (C–D) trials (42). At the present time, 
adjuvant chemotherapy is not recommended for DIPG outside 
of a clinical trial.
impediments to Chemotherapy/Targeted 
Therapy
One of the major limitations of DIPG treatment is the successful 
and efficient delivery of effective therapies to the tumor. For a 
drug or a targeted therapeutic agent to be effective, the active 
compound: (a) should reach its target in the tumor cells, (b) in 
adequate concentrations/bind to the target present in the tumor 
cells, (c) for an adequate amount of time for tumor cytotoxicity, 
and (d) the tumor cells themselves should be sensitive to the drug/
agent. There are several factors that can affect drug concentra-
tions within the DIPG tumor (105). These include bio-availability 
of the drug/agent (serum levels, protein/tissue binding), rate of 
blood flow to the tumor, degree of brain penetration [blood–brain 
barrier (BBB) and blood tumor barrier] and drug metabolism. 
The BBB is frequently intact in DIPG and plays an active role in 
restricting the delivery of systemically administered conventional 
and biological therapies (106). This often leads to decreased effec-
tive concentration of the therapeutic agents in the tumor.
In order to overcome the restrictive ability of the BBB, several 
alternative drug delivery strategies have been tried including: 
transient osmotic disruption of the BBB, enhancing the lipophilic-
ity of drugs, inhibition of membrane efflux pumps, intra-arterial/
intra-thecal chemotherapy, intra-nasal chemotherapy, direct 
intra-tumoral chemotherapy, etc., but each has met with minimal 
success (107). The most clinically proven approach to increase 
drug penetration into the CNS is to reversibly disrupt the junc-
tions formed by the endothelial cells to enhance their penetration 
through intercellular junctions. This can be accomplished through 
the use of osmotic agents or pharmacologically through the tar-
geting of membrane receptors that alter BBB permeability. While 
osmotic agents such as mannitol have been used to modulate 
BBB permeability in both pre-clinical and clinical settings (107) 
the major drawback with osmotic disruption is the long recovery 
period required for reestablishment of BBB integrity (108). With 
several hours required for the return of normal BBB function, 
patients are susceptible to toxicity (109). On the other hand, 
pharmacological agents such as RMP-7/Cereport, a bradykinin 
receptor agonist, have been shown to transiently disrupt the BBB 
in various animal models (108, 110). However, these agents have 
failed to produce the desired response in clinical trials due to 
non-uniform disruption of the BBB (83, 86, 110). Veringa et al. 
(106) using patient derived cell cultures and tumors showed that 
DIPG cells express MRP1 and the tumor vasculature exhibits 
drug efflux transporters (P-gp, MRP1, and BCRP1). However, 
cell cultures were sensitive to an array of chemotherapeutic agents 
when treated in  vitro. The concurrent use of efflux inhibitors 
(111) along with chemotherapy might improve the efficacy of 
chemotherapy and could be considered in a prospective clinical 
trial. Convection-enhanced delivery (CED), using external or 
implantable subcutaneous pumps, allows intra-tumoral injection 
of novel therapeutic agents (chemotherapy, cytotoxic interleukins, 
radio-immunotherapeutic agents), and there are ongoing phase I/
II clinical trials in DIPG.
Biological Targeted Therapy
Due to the availability of tumor tissue (from both autopsy and 
surgical biopsy samples) in several centers across the world, novel 
targets have been identified in DIPG and there are several ongoing 
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clinical trials using targeted therapies. The reader is referred to 
excellent reviews summarizing the past and ongoing clinical trials 
involving targeted therapies in DIPG (112–114). However, none 
of these trials have shown any superior survival benefit when 
compared to RT alone (Table 5) (115–129).
immunological/vaccine Therapy
Immunotherapy in DIPG is limited due to the non-availability of 
tumor tissue to identify and generate tumor-associated antigens. 
Li et  al. (130) evaluated the expression of Epidermal Growth 
Factor Receptor variant III (EGFRvIII) in postmortem DIPG tis-
sue and primary cell cultures using various laboratory techniques 
(immunohistochemistry/IHC, western blot, RT-PCR, and flow 
cytometry). IHC revealed expression of EGFRvIII in four of nine 
cases and the staining pattern was similar to the adult tumors. 
Overall expression was detected in 6 of 11 cases. There are several 
ongoing phase III clinical trials using a peptide vaccine targeting 
EGFRvIII in the treatment of newly diagnosed GBM in adults. 
Zhou et al. (131) evaluated the expression of B7-H3, a membrane 
protein (CD276) against which a therapeutic monoclonal anti-
body is available (8H9). IHC revealed B7-H3 immunoreactivity 
in 100% (n = 9/9) of postmortem DIPG samples.
Pollack et al. (132) conducted a pilot study using a peptide-
based vaccine against novel GAA [Glioma associated anti-
gens  –  EphA2, interleukin-13 receptor alpha2 (IL-13Rα2), and 
survivin]-derived epitopes in children with DIPG and HGGs. 
Newly diagnosed DIPG patients [treated with RT alone (N = 14) 
and RT + chemotherapy (N = 8)] were administered the vaccine 
in conjunction with immuno-adjuvant polyinosinic-polycytidylic 
acid (poly [I: C]) stabilized by lysine and carboxymethylcellulose 
(poly-ICLC). Five children had symptomatic pseudo-progression, 
which responded to dexamethasone and was associated with 
prolonged survival. The vaccine was well tolerated overall with 
good clinical (OS between 6.3 to >38 months) and immunologi-
cal response (positive anti-GAA immune response in 8 patients). 
Based upon the feasibility, safety, and potential promise of these 
studies, immune-based therapeutic strategies are expected to be 
offered in prospective phase II and III clinical trials.
PROGNOSTiC/BiOLOGiC MARKeRS  
iN DiPG
Although the outcome of DIPG is extremely poor and uniformly 
fatal, there are a sub-group of patients who survive longer. Some 
of the favorable clinical prognostic factors are young age at diag-
nosis (<3 years), prolonged interval between onset of symptoms 
and diagnosis (>6 months) and absence of cranial nerve palsies or 
long tract involvement at presentation. Tools to assess the efficacy 
of treatment and monitoring in DIPG are evolving. The RANO 
(Response Assessment in Neuro-oncology) criteria (using MRI) 
are used to assess response during or post chemotherapy/targeted 
therapy with decrease in steroid use, tumor size and improved 
neurologic symptoms indicative of response to therapy. However, 
DIPG tumors frequently do not enhance or may exhibit variable 
patterns of enhancement and either decrease in tumor size is 
not sustained or this does not translate into improved survival 
(133). Moreover, conventional MRI instructs us regarding tumor 
structure and location and cannot reliably differentiate therapy-
related phenomena such as efficacy, pseudo-progression, or 
pseudo-response (133). Hipp et al. (134) used prospective multi-
parametric imaging to evaluate outcome in children with DIPG. 
In their study, increased perfusion [using dynamic susceptibility 
contrast (DSC) MRI] at any single time point was associated 
with shorter survival (RR = 4.91), and increasing perfusion over 
time was a poor prognostic factor. Steffen-Smith et  al. (135) 
used Magnetic Resonance Spectroscopy (MRS) techniques to 
monitor DIPG patients throughout their course of treatment. In 
their study, the choline: N-acetylaspartate ratio (CHO:NAA) was 
shown to be prognostic; patients with a CHO:NAA ratio higher 
than the median of 2.1 demonstrated a greater risk of early mor-
tality compared to patients with a ratio of ≤2.1. During follow-up, 
changes in this ratio had an impact on prognosis with increase in 
the CHO: NAA ratio being inversely associated with survival and 
decreasing CHO: NAA ratio being associated with a longer life 
expectancy. Although very promising, these imaging modalities 
are limited by their availability in specialized centers and only as 
part of research protocols.
Diffuse intrinsic pontine glioma patients who have histone 
mutations (H3.3 and H3.1, K27M) identified by IHC and other 
methods have a worse OS when compared to wild-type tumors, 
and this association is independent of patient age and histological 
diagnosis. Jansen et al. (136) recently developed a DIPG survival 
prediction tool that can be used for predicting outcome and risk 
stratification for prospective future clinical trials. Multivariate 
Cox proportional hazards analysis was used to pick both positive 
prognostic predictors (longer symptom duration, age ≤3  years 
and use of concurrent oral and intravenous chemotherapy with 
RT) and negative predictor (presence of ring enhancement in 
contrast MRI). The risk score calculated based on these predictors 
will not only able to predict the prognosis but also stratify patients 
into risk groups (standard, intermediate, and high), which can be 
used in future clinical trials. This prediction model itself requires 
validation in a prospective clinical trial.
SUMMARY
In summary, diagnostic and therapeutic failures of the past and 
recent advances in the genomics and biology of DIPG have 
made us wiser in the following ways: (1) we now understand that 
DIPG is a heterogeneous group of tumors with origins that can 
be traced to aberrant neurodevelopment and it is biologically 
distinct from other pediatric and adult HGG. Therefore, adapt-
ing chemotherapy and/or targeted therapy used in pediatric 
and adult HGG for DIPG should be abandoned. (2) biopsy of 
DIPG is relatively safe using modern neurosurgical techniques 
and should be considered in the context of clinical trials. Biopsy 
results will confirm the diagnosis, may identify actionable tar-
gets, and with the use of appropriate prediction tools, help us to 
risk-stratify these patients for both therapy and prognosis. (3) 
there is evidence in the literature to suggest that DIPG is a whole 
brain disease and this may support whole neuraxis imaging at 
diagnosis, during therapy and at follow-up. (4) previous decades 
of treatment failure may be attributed to several factors, includ-
ing: inadequate drug levels within the tumor due to lack of BBB 
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